Guanfacine is an adrenergic neuron-blocking agent—classified as a drug affecting the circulatory system—primarily used to treat moderate to severe hypertension. It acts as a central alpha-2 receptor agonist; its antihypertensive potency is one-tenth that of clonidine, requiring a dosage 7 to 10 times higher, while its sedative effect is relatively mild. Following oral administration, it is rapidly and completely absorbed, with a half-life of approximately 21 hours and relatively low plasma concentrations. The initial dosage is 0.5–1 mg taken at bedtime, which may be increased to a maximum of 3 mg daily. Common adverse reactions include dry mouth, drowsiness, and orthostatic hypotension; abrupt discontinuation may lead to withdrawal symptoms such as headache and palpitations. Its use is contraindicated in pregnant and breastfeeding women, and it should be used with caution in patients with cardiovascular disease.
Guanfacine is an adrenergic neuron-blocking agent—classified as a drug affecting the circulatory system—primarily used to treat moderate to severe hypertension. It acts as a central alpha-2 receptor agonist; its antihypertensive potency is one-tenth that of clonidine, requiring a dosage 7 to 10 times higher, while its sedative effect is relatively mild. Following oral administration, it is rapidly and completely absorbed, with a half-life of approximately 21 hours and relatively low plasma concentrations. The initial dosage is 0.5–1 mg taken at bedtime, which may be increased to a maximum of 3 mg daily. Common adverse reactions include dry mouth, drowsiness, and orthostatic hypotension; abrupt discontinuation may lead to withdrawal symptoms such as headache and palpitations. Its use is contraindicated in pregnant and breastfeeding women, and it should be used with caution in patients with cardiovascular disease.
Guanfacine is an adrenergic neuron-blocking agent—classified as a drug affecting the circulatory system—primarily used to treat moderate to severe hypertension. It acts as a central alpha-2 receptor agonist; its antihypertensive potency is one-tenth that of clonidine, requiring a dosage 7 to 10 times higher, while its sedative effect is relatively mild. Following oral administration, it is rapidly and completely absorbed, with a half-life of approximately 21 hours and relatively low plasma concentrations. The initial dosage is 0.5–1 mg taken at bedtime, which may be increased to a maximum of 3 mg daily. Common adverse reactions include dry mouth, drowsiness, and orthostatic hypotension; abrupt discontinuation may lead to withdrawal symptoms such as headache and palpitations. Its use is contraindicated in pregnant and breastfeeding women, and it should be used with caution in patients with cardiovascular disease.
Guanfacine is an adrenergic neuron-blocking agent—classified as a drug affecting the circulatory system—primarily used to treat moderate to severe hypertension. It acts as a central alpha-2 receptor agonist; its antihypertensive potency is one-tenth that of clonidine, requiring a dosage 7 to 10 times higher, while its sedative effect is relatively mild. Following oral administration, it is rapidly and completely absorbed, with a half-life of approximately 21 hours and relatively low plasma concentrations. The initial dosage is 0.5–1 mg taken at bedtime, which may be increased to a maximum of 3 mg daily. Common adverse reactions include dry mouth, drowsiness, and orthostatic hypotension; abrupt discontinuation may lead to withdrawal symptoms such as headache and palpitations. Its use is contraindicated in pregnant and breastfeeding women, and it should be used with caution in patients with cardiovascular disease.Guanfacine is an adrenergic neuron-blocking agent—classified as a drug affecting the circulatory system—primarily used to treat moderate to severe hypertension. It acts as a central alpha-2 receptor agonist; its antihypertensive potency is one-tenth that of clonidine, requiring a dosage 7 to 10 times higher, while its sedative effect is relatively mild. Following oral administration, it is rapidly and completely absorbed, with a half-life of approximately 21 hours and relatively low plasma concentrations. The initial dosage is 0.5–1 mg taken at bedtime, which may be increased to a maximum of 3 mg daily. Common adverse reactions include dry mouth, drowsiness, and orthostatic hypotension; abrupt discontinuation may lead to withdrawal symptoms such as headache and palpitations. Its use is contraindicated in pregnant and breastfeeding women, and it should be used with caution in patients with cardiovascular disease.
Guanfacine is an adrenergic neuron-blocking agent—classified as a drug affecting the circulatory system—primarily used to treat moderate to severe hypertension. It acts as a central alpha-2 receptor agonist; its antihypertensive potency is one-tenth that of clonidine, requiring a dosage 7 to 10 times higher, while its sedative effect is relatively mild. Following oral administration, it is rapidly and completely absorbed, with a half-life of approximately 21 hours and relatively low plasma concentrations. The initial dosage is 0.5–1 mg taken at bedtime, which may be increased to a maximum of 3 mg daily. Common adverse reactions include dry mouth, drowsiness, and orthostatic hypotension; abrupt discontinuation may lead to withdrawal symptoms such as headache and palpitations. Its use is contraindicated in pregnant and breastfeeding women, and it should be used with caution in patients with cardiovascular disease.
Guanfacine is an adrenergic neuron-blocking agent—classified as a drug affecting the circulatory system—primarily used to treat moderate to severe hypertension. It acts as a central alpha-2 receptor agonist; its antihypertensive potency is one-tenth that of clonidine, requiring a dosage 7 to 10 times higher, while its sedative effect is relatively mild. Following oral administration, it is rapidly and completely absorbed, with a half-life of approximately 21 hours and relatively low plasma concentrations. The initial dosage is 0.5–1 mg taken at bedtime, which may be increased to a maximum of 3 mg daily. Common adverse reactions include dry mouth, drowsiness, and orthostatic hypotension; abrupt discontinuation may lead to withdrawal symptoms such as headache and palpitations. Its use is contraindicated in pregnant and breastfeeding women, and it should be used with caution in patients with cardiovascular disease.vGuanfacine is an adrenergic neuron-blocking agent—classified as a drug affecting the circulatory system—primarily used to treat moderate to severe hypertension. It acts as a central alpha-2 receptor agonist; its antihypertensive potency is one-tenth that of clonidine, requiring a dosage 7 to 10 times higher, while its sedative effect is relatively mild. Following oral administration, it is rapidly and completely absorbed, with a half-life of approximately 21 hours and relatively low plasma concentrations. The initial dosage is 0.5–1 mg taken at bedtime, which may be increased to a maximum of 3 mg daily. Common adverse reactions include dry mouth, drowsiness, and orthostatic hypotension; abrupt discontinuation may lead to withdrawal symptoms such as headache and palpitations. Its use is contraindicated in pregnant and breastfeeding women, and it should be used with caution in patients with cardiovascular disease.
Guanfacine is an adrenergic neuron-blocking agent—classified as a drug affecting the circulatory system—primarily used to treat moderate to severe hypertension. It acts as a central alpha-2 receptor agonist; its antihypertensive potency is one-tenth that of clonidine, requiring a dosage 7 to 10 times higher, while its sedative effect is relatively mild. Following oral administration, it is rapidly and completely absorbed, with a half-life of approximately 21 hours and relatively low plasma concentrations. The initial dosage is 0.5–1 mg taken at bedtime, which may be increased to a maximum of 3 mg daily. Common adverse reactions include dry mouth, drowsiness, and orthostatic hypotension; abrupt discontinuation may lead to withdrawal symptoms such as headache and palpitations. Its use is contraindicated in pregnant and breastfeeding women, and it should be used with caution in patients with cardiovascular disease.
Guanfacine is an adrenergic neuron-blocking agent—classified as a drug affecting the circulatory system—primarily used to treat moderate to severe hypertension. It acts as a central alpha-2 receptor agonist; its antihypertensive potency is one-tenth that of clonidine, requiring a dosage 7 to 10 times higher, while its sedative effect is relatively mild. Following oral administration, it is rapidly and completely absorbed, with a half-life of approximately 21 hours and relatively low plasma concentrations. The initial dosage is 0.5–1 mg taken at bedtime, which may be increased to a maximum of 3 mg daily. Common adverse reactions include dry mouth, drowsiness, and orthostatic hypotension; abrupt discontinuation may lead to withdrawal symptoms such as headache and palpitations. Its use is contraindicated in pregnant and breastfeeding women, and it should be used with caution in patients with cardiovascular disease.
Guanfacine is an adrenergic neuron-blocking agent—classified as a drug affecting the circulatory system—primarily used to treat moderate to severe hypertension. It acts as a central alpha-2 receptor agonist; its antihypertensive potency is one-tenth that of clonidine, requiring a dosage 7 to 10 times higher, while its sedative effect is relatively mild. Following oral administration, it is rapidly and completely absorbed, with a half-life of approximately 21 hours and relatively low plasma concentrations. The initial dosage is 0.5–1 mg taken at bedtime, which may be increased to a maximum of 3 mg daily. Common adverse reactions include dry mouth, drowsiness, and orthostatic hypotension; abrupt discontinuation may lead to withdrawal symptoms such as headache and palpitations. Its use is contraindicated in pregnant and breastfeeding women, and it should be used with caution in patients with cardiovascular disease.
Guanfacine is an adrenergic neuron-blocking agent—classified as a drug affecting the circulatory system—primarily used to treat moderate to severe hypertension. It acts as a central alpha-2 receptor agonist; its antihypertensive potency is one-tenth that of clonidine, requiring a dosage 7 to 10 times higher, while its sedative effect is relatively mild. Following oral administration, it is rapidly and completely absorbed, with a half-life of approximately 21 hours and relatively low plasma concentrations. The initial dosage is 0.5–1 mg taken at bedtime, which may be increased to a maximum of 3 mg daily. Common adverse reactions include dry mouth, drowsiness, and orthostatic hypotension; abrupt discontinuation may lead to withdrawal symptoms such as headache and palpitations. Its use is contraindicated in pregnant and breastfeeding women, and it should be used with caution in patients with cardiovascular disease.
Guanfacine is an adrenergic neuron-blocking agent—classified as a drug affecting the circulatory system—primarily used to treat moderate to severe hypertension. It acts as a central alpha-2 receptor agonist; its antihypertensive potency is one-tenth that of clonidine, requiring a dosage 7 to 10 times higher, while its sedative effect is relatively mild. Following oral administration, it is rapidly and completely absorbed, with a half-life of approximately 21 hours and relatively low plasma concentrations. The initial dosage is 0.5–1 mg taken at bedtime, which may be increased to a maximum of 3 mg daily. Common adverse reactions include dry mouth, drowsiness, and orthostatic hypotension; abrupt discontinuation may lead to withdrawal symptoms such as headache and palpitations. Its use is contraindicated in pregnant and breastfeeding women, and it should be used with caution in patients with cardiovascular disease.
Guanfacine is an adrenergic neuron-blocking agent—classified as a drug affecting the circulatory system—primarily used to treat moderate to severe hypertension. It acts as a central alpha-2 receptor agonist; its antihypertensive potency is one-tenth that of clonidine, requiring a dosage 7 to 10 times higher, while its sedative effect is relatively mild. Following oral administration, it is rapidly and completely absorbed, with a half-life of approximately 21 hours and relatively low plasma concentrations. The initial dosage is 0.5–1 mg taken at bedtime, which may be increased to a maximum of 3 mg daily. Common adverse reactions include dry mouth, drowsiness, and orthostatic hypotension; abrupt discontinuation may lead to withdrawal symptoms such as headache and palpitations. Its use is contraindicated in pregnant and breastfeeding women, and it should be used with caution in patients with cardiovascular disease.
Guanfacine is an adrenergic neuron-blocking agent—classified as a drug affecting the circulatory system—primarily used to treat moderate to severe hypertension. It acts as a central alpha-2 receptor agonist; its antihypertensive potency is one-tenth that of clonidine, requiring a dosage 7 to 10 times higher, while its sedative effect is relatively mild. Following oral administration, it is rapidly and completely absorbed, with a half-life of approximately 21 hours and relatively low plasma concentrations. The initial dosage is 0.5–1 mg taken at bedtime, which may be increased to a maximum of 3 mg daily. Common adverse reactions include dry mouth, drowsiness, and orthostatic hypotension; abrupt discontinuation may lead to withdrawal symptoms such as headache and palpitations. Its use is contraindicated in pregnant and breastfeeding women, and it should be used with caution in patients with cardiovascular disease.
Guanfacine is an adrenergic neuron-blocking agent—classified as a drug affecting the circulatory system—primarily used to treat moderate to severe hypertension. It acts as a central alpha-2 receptor agonist; its antihypertensive potency is one-tenth that of clonidine, requiring a dosage 7 to 10 times higher, while its sedative effect is relatively mild. Following oral administration, it is rapidly and completely absorbed, with a half-life of approximately 21 hours and relatively low plasma concentrations. The initial dosage is 0.5–1 mg taken at bedtime, which may be increased to a maximum of 3 mg daily. Common adverse reactions include dry mouth, drowsiness, and orthostatic hypotension; abrupt discontinuation may lead to withdrawal symptoms such as headache and palpitations. Its use is contraindicated in pregnant and breastfeeding women, and it should be used with caution in patients with cardiovascular disease.
TDS
Greece
Russia
United States
